15,903 results on '"NEUROFIBROMATOSIS 1"'
Search Results
2. A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
3. Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
4. Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
5. A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
6. Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
7. AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
8. Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
9. A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients with Neurofibromatosis Type 1 (INSPIRE-NF1)
10. A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
11. Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
12. Natural History Study of Patients With Neurofibromatosis Type I
13. Natural History Study of Patients With Neurofibromatosis Type 2
14. Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
15. PASS of Paediatric Patients Initiating Selumetinib
16. Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
17. Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
18. Real-World Treatment Study of Koselugo (Selumetinib)
19. Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
20. A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
21. A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
22. FARD (RaDiCo Cohort) (RaDiCo-FARD) (FARD)
23. Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
24. MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
25. Study of Cabozantinib with Selumetinib for Plexiform Neurofibromas (NF113)
26. Pediatric Long-Term Follow-up and Rollover Study
27. Phase II Study of Binimetinib in Children and Adults with NF1 Plexiform Neurofibromas (NF108-BINI)
28. Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
29. Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
30. Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: a Clinical Translational Approach.
31. Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
32. Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 (NF114)
33. Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
34. Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST (MEKMDM2)
35. Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to (SPRINKLE)
36. Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
37. Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
38. MicroRNAs in Patients With Neurofibromatosis Type 1
39. Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
40. Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults with Neurofibromatosis Type 1
41. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2)
42. Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
43. A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
44. MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
45. Molecular Aspects of Preimplantation Genetic Diagnosis for NF1 (NF1)
46. MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)
47. Natural History Study of Cutaneous Neurofibromas in People With NF1 (cNF Natural Hx)
48. Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 (NF1NAC)
49. Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (DoDNAC)
50. RASopathy Biorepository
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.